within Pharmacolibrary.Drugs.ATC.N;

model N02CA01_2
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.063,
    Cl             = 90 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,
    adminCount     = 1,
    Vd             = 0.223,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Dihydroergotamine is an ergot alkaloid medication primarily used for the treatment of migraine headaches and cluster headaches. It acts as a vasoconstrictor of intracranial arteries, and as an agonist at serotonin (5-HT1) receptors. It is approved and still in use for acute migraine attacks by several regulatory agencies.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration in adults, since bioavailability is extremely low and no direct population PK model reported.</p><h4>References</h4><ol><li><p>Lipton, RB, et al., &amp; Albrecht, D (2025). Relationship of dihydroergotamine pharmacokinetics, clinical efficacy, and nausea-A narrative review. <i>Headache</i> 65(3) 527–535. DOI:<a href=&quot;https://doi.org/10.1111/head.14877&quot;>10.1111/head.14877</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39601088/&quot;>https://pubmed.ncbi.nlm.nih.gov/39601088</a></p></li><li><p>Humbert, H, et al., &amp; Lavène, D (1996). Human pharmacokinetics of dihydroergotamine administered by nasal spray. <i>Clinical pharmacology and therapeutics</i> 60(3) 265–275. DOI:<a href=&quot;https://doi.org/10.1016/S0009-9236(96)90053-3&quot;>10.1016/S0009-9236(96)90053-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8841149/&quot;>https://pubmed.ncbi.nlm.nih.gov/8841149</a></p></li><li><p>de Marées, H, et al., &amp; Knaup, G (1986). Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing. <i>European journal of clinical pharmacology</i> 30(6) 685–689. DOI:<a href=&quot;https://doi.org/10.1007/BF00608216&quot;>10.1007/BF00608216</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3533566/&quot;>https://pubmed.ncbi.nlm.nih.gov/3533566</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02CA01_2;
